SIRFLOX Complete Response Case Study

A 58-year-old male patient with liver-only metastases and a primary tumor in situ was treated with mFOLFOX6 + bevacizumab + SIR-Spheres® Y-90 resin microspheres in the SIRFLOX study. The patient was diagnosed with rectal cancer and synchronous mCRC liver metastases one month prior to randomization. He had not received prior chemotherapy or radiotherapy and had a WHO performance status of 0.

The patient experienced a partial response (PR) from first imaging assessment through to 22.0 months post-randomization. At 25.3 months post-randomization, the patient experienced a complete response (CR). The last cycle of chemotherapy was given 40.2 months post-randomization. The patient continued to experience a CR at all imaging assessments through to the final study follow up, 55.9 months post-randomization.

This video shows a 3D reconstruction of the CT scans of the patient’s liver before and after treatment.

 Play Video

CT images

Complete Response Baseline
Baseline Imaging: Patient measured as having 11% tumor burden

Complete Response 4.7 Years
Imaging at 4.7 years after treatment: Patient had a sustained and durable Complete Response

 

SIRFLOX Partial Response Case Study

A 61-year-old female patient with liver-only metastases and a primary tumor in situ was treated with mFOLFOX6 + SIR-Spheres Y-90 resin microspheres in the SIRFLOX study. The patient was diagnosed with colon cancer and liver metastases 1.6 month prior to randomization. She had not received prior chemotherapy or radiotherapy and had a WHO performance status of 0.

At first imaging assessment, 1.9 months post-randomization, the patient initially experienced stable disease (SD) and at second imaging assessment, 3.0 months post-randomization, the patient experienced a partial response (PR). The last cycle of chemotherapy was given 16.5 months post-randomization, at which time the patient was experiencing peripheral neuropathy. The PR lasted through to the patient’s final study follow up, 29.0 months post-randomization. At the final imaging assessment, the patient had an estimated 79% reduction in the sum of longest diameters of the five target lesions.

This video shows a 3D reconstruction of the CT scans of the patient’s liver before and after treatment.

Play Video

CT images

Partial Response Baseline
Baseline Imaging: Patient measured as having 14% tumor burden

Partial Response 2.4 Years
Imaging at 2.4 years after treatment: Patient had ~79% tumor shrinkage, with a sustained Partial Response



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×